

FORM PTO-1390 (REV. 1-98)	U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 3528.38.US00
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U S APPLICATION NO (If known, see 37 CFR 1.5) 09/171854
INTERNATIONAL APPLICATION NO PCT/DE97/00814	INTERNATIONAL FILING DATE April 23, 1997	PRIORITY DATE CLAIMED April 24, 1996

TITLE OF INVENTION IDENTIFICATION OF NUMERICAL CHANGES IN CELL DNA	
APPLICANT(S) FOR DO/EO/US Stefan JOOS and Peter LICHTER	

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. **(3 pages)**
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau). **(15 pages - 2 shts drwgs)**
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US)
6. A translation of the International Application into English (35 U.S.C 371(c)(2)). **(17 pgs; 2 pgs amended claims and 2 shts drwgs)**
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). **(2 pages)**
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4))
10. A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A FIRST preliminary amendment
- A SECOND or SUBSEQUENT preliminary amendment.
14. A substitute specification, **2 shts drwgs; and transmittal letter (15 pages)**
15. A change of power of attorney and/or address letter.
16. Other items or information: **copy of International Search Report (PCT/ISA/210 - 4 pages); and copy of first page to publication of the PCT application under No. WO 97/40185. International Preliminary Examination Report (6 pages)**

17. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1070.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$930.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$790.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$720.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$98.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 930.00Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	8 - 20 =	0	x \$22.00	\$ 0.00
Independent claims	1 - 3 =	0	x \$82.00	\$ 0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$
				TOTAL OF ABOVE CALCULATIONS = \$ 930.00
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			+ \$	
				SUBTOTAL = \$ 930.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$	
				TOTAL NATIONAL FEE = \$ 930.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property			+ \$	
				TOTAL FEES ENCLOSED = \$ 930.00
				Amount to be refunded: \$
				charged: \$

a. A check in the amount of \$ 930.00 to cover the above fees is enclosed.b. Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 08-3038. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Albert P. Halluin
HOWREY & SIMON
1299 Pennsylvania Avenue, N.W.
Box 34
Washington, D.C. 20004
Telephone: 650/463-8100
Facsimile: 202/383-7195



SIGNATURE

for **Albert P. Halluin**

NAME

25,227
REGISTRATION NUMBER

Identification of Numerical Changes in Cell DNA

The invention relates to a process for identifying numerical changes in cell DNA and a kit suitable for carrying out the process.

For the field of molecular tumor genetics it is important to know which genetic changes and cytogenetic changes, respectively, are present in certain tumors, in which sequence they form and whether they are correlated with the clinical course, e.g. in the case of a treatment. In order to find this out it would be necessary to investigate the DNA of small cell populations of the tumors and single-cells thereof, respectively. Many attempts have been made to achieve this goal. However, the previous results are not satisfactory.

Therefore, it is the object of the present invention to provide a process by which it is possible to identify genetic changes and cytogenetic changes, respectively, in the DNA of small cell populations and single cells, respectively.

According to the invention this is achieved by the subject matters defined in the claims.

Thus, the subject matter of the present invention relates to a process for detecting numerical changes in cell DNA, which comprises the following steps:

- (a) isolation of DNA from normal cells and amplification of the DNA by means of a PCR method using tag primers,
- (b) *in situ* hybridization of the cells under study with the amplified DNA from (a),

- (c) amplification of DNA from the *in situ* hybridized cells from (b) by means of a PCR method using the tag primers from (a), and
- (d) identification of numerical changes in the amplified DNA from (c) in a normal way.

The expression "normal cells" comprises cells of any kind and origin, which have no known numerical changes in their DNA.

DNA is isolated and amplified from such cells. Common methods can be used for this purpose. For the amplification a PCR method offers itself which uses tag primers. The expression "tag" refers to the fact that the primers can be degenerative (universal) primers, i.e. primers are concerned which can bind to many different sites of a cell DNA. Examples of such primers are DOP or SiA primers.

The expression "cells under study" comprises cells of any kind and origin. In particular, these are tumor cells or cells from the blood of pregnant persons. Cells of a small cell population or single cells are particularly preferred. Most preferred are cells having an interphase nucleus.

The cells under study are subjected to an *in situ* hybridization with the amplified DNA from the healthy cells. For this purpose, common conditions and materials can be chosen.

The DNA from the *in situ* hybridized cells is used as a template for an amplification. For this purpose, a PCR method offers itself which uses the above tag primers correspondingly.

The amplified DNA is used to determine numerical changes. For this purpose, common methods can be carried out. It is favorable to carry out a comparative genomic hybridization

DEUTSCHE FEDERATION FÜR GENETISCHE FORSCHUNG

method (CGH) (cf. Kallioniemi A., et al., *Science* 258:818, 1992, Kallioniemi O.-P., et al., *Genes Chromosome Cancer*, 10:231, 1994, and Lichter P., et al. in *Human Chromosomes*, eds. Verma R.S. and Babu A., New York, 1995, p. 191).

According to the invention a kit is also provided for carrying out the process for identifying numerical changes in the DNA of cells, particularly of a small cell population or single cells. Such a kit comprises the following components:

- (a) amplified DNA from healthy cells, the DNA being flanked by tag primers,
- (b) tag primers, and common
- (c) auxiliary agents, particularly those suitable for identifying numerical changes in a DNA.

By means of the present invention it is possible to identify numerical changes in the DNA of cells, particularly of small cell populations and single cells. Thus, the present invention is adapted for use in the diagnostics of diseases in which the investigations of smallest tissue samples and cell aggregates matter. Such diseases are particularly tumoral diseases. Furthermore, the present invention is suitable to examine embryonic cells in the blood of pregnant persons. Hence it represents a new possibility for prenatal diagnostics.

Brief description of the drawings:

Fig. 1 shows a diagram of the process according to the invention, and

fig. 2 shows chromosomal over-representations in the cell line Colo 320HSR with and without use of the "Tagged Genome Hybridization" (TGH) process according to the invention.

The following example explains the invention.

**Example: Analysis of small cell populations of cell line
Colo 320(HSR) by the process according to the
invention**

The process according to the invention (TGH process, cf. fig. 1) is carried out below with cell line Colo 320(HSR). The TGH process proceeds in several individual steps:

- Preparation of Colo 320(HSR) interphase nuclei on slides.
- Preparation of a tag-labeled sequence pool of normal genomic DNA by means of DOP PCR.
- Modification of the tag-labeled genomic DNA.
- *In situ* hybridization of the tag-labeled genomic DNA on interphase nuclei of cell line Colo 320(HSR).
- Isolation of Colo 320(HSR) cell populations of defined number by means of micromanipulation. To elucidate the efficiency of the TGH treatment, both cell nuclei hybridized with tag-labeled DNA and non-hybridized cell nuclei were isolated and then compared.
- DNA amplification of the isolated cell nuclei by means of DOP PCR.
- Process of comparative genomic hybridization (CGH) for identifying chromosomal imbalances of Colo 320(HSR) cells.

As far as the preparation of the interphase nuclei, the isolation of genomic DNA from blood and the CGH protocol are concerned, reference is made to known methods (cf. Kallioniemi A., et al., *Science* 258:818, 1992, Kallioniemi O.-P., et al., *Genes Chromosome Cancer*, 10:231, 1994, and Lichter P., et al. in *Human Chromosomes*, eds. Verma R.S. and Babu A., New York, 1995, p. 191).

Step 1

Preparation of a tag-labeled sequence pool of normal genomic DNA by means of DOP PCR.

Reagents, buffers and solutions:

- 10x reaction buffer: 20 mM MgCl₂; 500 mM KCl; 100 mM Tris-HCl (pH 8.4); 1 mg/ml gelatin.
- 10x nucleotide-mix: 2 mM of each nucleotide (dATP, dCTP, dGTP, dTTP (prepared from the deoxynucleoside triphosphate set from Boehringer Mannheim, Germany, catalog No. 1277049)).
- 10x DOP primer: 20 μ M of oligonucleotide 5'CCG ACT CGA GNN NNN NAT GTG G3', (N = A, C, G or T).
- For minigels: agarose; TBE buffer: 0.089 M Tris-borate, 0.089 M boric acid, 2 mM EDTA (pH 8.0); suitable size marker (e.g. 1 kb marker; catalog No. 15615-016; Gibco BRL, Eggenstein, Germany); gel loading buffer having 0.25 % bromophenol blue and 30 % glycerol.
- Starting DNA of normal cells, to be labeled and amplified, respectively.

Detailed course:

1. The following components were pipetted on ice into a 500 μ l reaction vessel (PCR vessels having integrated volume restriction; Sarstedt, Nümbrecht, Germany) (total volume 50 μ l):

100 ng genomic starting DNA
5 μ l 10x reaction buffer
5 μ l 10x nucleotide mix
5 μ l 10x DOP primer
H₂O ad 50 μ l
1.25 U taq polymerase (should be added last).

2. The same components were transferred with a pipette as negative control but without the addition of the starting DNA.

3. A device from Omniprobe/Hybaid (Type AZ 1623; supplier MWG Biotech Ebersbach near München, Germany) was used for the PCR reactions. The following temperature program was employed:

- initial denaturation of the starting DNA by heating to 93°C for 10 min.
- 5 cycles (what is called "low stringency phase") each with:
94°C, 1 min.; 30°C, 3 min.; 30°C-72°C, 3 min.; 72°C, 3 min.
- 35 cycles (what is called "high stringency phase") each with:
94°C, 1 min.; 62°C, 1 min.; 72°C, 3 min. (with an extension of 1 sec/cycle);
- a final extension step at 72°C for 10 min.

4. After the PCR reaction, an aliquot of 7 µl of the product was separated on an agarose gel. A 1 kb marker served as the size marker. The separation was made in 1x TBE buffer with 100 V for 30 min. The applied DNA was made visible by staining using ethidium bromide and photographed. A "smear" with DNA fragments between 200 base pairs and 2000 base pairs was usually visible. No DNA was identifiable within this size range in the negative control.

5. Finally, the rest of the nucleotides were separated from the tag-labeled DNA by means of a PCR purification kit (Diagen GmbH, Hilden, Germany, catalog No. 28106).

Step 2

Modification of the tag-labeled genomic DNA for the *in situ* hybridization.

Reagents, buffers and solutions

- 10x reaction buffer with 0.5 M Tris-HCl (pH 8.0), 50 mM MgCl₂, 0.5 mg/ml bovine serum albumin (fraction V, catalog No. 735078, Boehringer Mannheim).
- 0.1 M β -mercaptoethanol.
- 10x nucleotide stock solution with 0.5 mM dATP, 0.5 mM dCTP, 0.5 mM dGTP, 0.125 mM digoxigenin-11-dUTP (Boehringer Mannheim, catalog No. 1558706), 0.375 mM dTTP.
- Escherichia coli-DNA-polymerase I (New England Biolabs GmbH, Schwalbach/Taunus, Germany, catalog No. 209L).
- DNase I stock solution: 3 mg in 1 ml 0.15 M NaCl, 50 % glycerol.
- Column buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.1 % SDS.
- Columns: Sephadex G50 (medium), 1 ml tuberculin syringes (e.g. "Primo" from Pharmoplast A/S, DK-4970 Rodby), glass wool.
- For Minigel: Agarose; TBE buffer; 1 kb size marker (Gibco BRL, Eggenstein, catalog No. 15615-016); gel loading buffer (see above).

Detailed course:

1. 2 μ g of the tag-labeled DNA (see step 1) were transferred with a pipette into a reaction vessel together with 10 μ l of the 10x reaction buffer, 10 μ l β -mercaptoethanol, 10 μ l of the nucleotide stock solution, 20 U of DNA-polymerase I, and 2 μ l of a 1:1000 dilution of the DNase stock solution (in water).
2. The modification reaction was carried out at 15°C for 30-40 min.
3. The reaction mixture was placed on ice and an aliquot was tested for the fragment size suitable for the *in situ* hybridization.
4. The fragment length of the DNA was determined by gel electrophoresis. 10 μ l of the reaction batch were

admixed with 3 μ l gel loading buffer and denatured in the boiling water bath for 2-3 min. After another 3 min. on ice, the aliquot was applied to a 1-2 % agarose minigel together with the 1 kb size marker. The DNA fragments were separated with 15 V/cm for 30 min. After staining using ethidium bromide, the gel could be photographed under U.V. light and the size of the DNA fragments could be determined.

5. In the optimum case, the DNA fragments should have a size range between 500 and 1000 base pairs. When the average size of the fragments was above this range, the remaining DNA was incubated once again with DNase I until the optimum size of the fragments was reached.
6. In order to inactivate the DNase, 2 μ l of 0.5 M EDTA (final concentration 10 mM) and 1 μ l 10 % SDS (final concentration 0.1 %) were added to the batch and the reaction batch was heated at 68°C for 10 min.
7. Non-incorporated nucleotides were separated from the DNA sample by gel filtration using separation columns, which had been produced as follows.
 - (a) A 1 ml tuberculin syringe was initially packed with glass wool up to the 0.2 ml mark and then filled with buffered Sephadex G50 up to the 1 ml mark. The column was transferred into a 15 ml vessel and centrifuged at 2000 g and room temperature for 6 min.
 - (b) After adding 100 μ l of column buffer each, the columns were centrifuged again. This step was repeated three times.
 - (c) The DNA was placed on the column, centrifuged (2000 g, 6 min.) and collected in a reaction vessel. The final concentration of this DNA sample is about 20 ng/ μ l. It can be stored at -20°C over a prolonged period of time (months to years).

Step 3

In situ hybridization of the tag-labeled genomic DNA on interphase nuclei of line Colo 320 (HSR).

A) Denaturation of the genomic DNA of the Colo 320(HSR) interphase nuclei.

Reagents, buffers and solutions:

- Denaturation solution: 70 % deionized formamide (for molecular biology, catalog No. 112027, Merck, Darmstadt, 2x SSC, 50 mM sodium phosphate (pH 7 with 1 M HCl).
- ethanol (ice-cold): 70 %, 90 % and 100 %.

Detailed course:

1. The denaturation solution was placed in a cuvette and heated in a water bath to 70°C.
2. The cover glasses (76 x 26 mm) including the Colo 320(HSR) cell nuclei under study were incubated in this solution for 2 min. precisely and then immediately transferred into the cold 70 % alcohol.
3. The cover glasses were dehydrated in 70 %, 90 % and 100 % ethanol for 5 min. each and then air-dried.

B) Precipitation and denaturation of the tag-labeled DNA sample for the *in situ* hybridization.

Reagents, buffers and solutions

- 3 M sodium acetate, pH 5.2.
- Deionized formamide (for molecular biology, catalog No. 112027, Merck, Darmstadt). The deionization was made by stirring the formamide with an ion exchanger (e.g. AG 501-X8 (D) Resin, catalog No. 142-6425 of Biorad, München, Germany).
- 2x hybridization buffer: 4x SSC, 20 % dextran sulfate.

Detailed course:

1. 1 μ g of the tag-labeled DNA and 50 μ g of human Cot1 DNA (Gibco-BRL, Eggenstein, catalog No. 5279SA) were precipitated by adding 1/20 volume of 3 M sodium acetate and 2.5 volumes of 100 % ethanol.
2. After centrifuging at 12,000 rpm and 4°C for 10 min., the supernatant was separated, the pellet was washed with 500 μ l 70 % ethanol, centrifuged again (12,000 rpm, 10 min., 4°C) and then lyophilized.
3. The precipitated DNA was inserted in 6 μ l deionized formamide and shaken at room temperature for 30 min. (Vortex).
4. After adding 6 μ l of 2x hybridization buffer, shaking was carried out again for 30 min.
5. The DNA was denatured at 75°C for 5 min., placed on ice for 5 min. and then incubated at 37°C for 30 min. ("preannealing").

C) *In situ hybridization**Detailed course:*

1. 12 μ l of the hybridization mix including the denatured DNA were placed on a large cover glass comprising the cell nuclei under study.
2. A cover glass having a size of 18 x 18 mm was placed thereon.
3. The 18 x 18 mm cover glass was sealed with liquid adhesive, and the preparation was incubated in a moist chamber at 37°C for 48 h.

B65371727T60

D) Washing and detection of the hybridized cell nuclei

Reagents, buffers and solutions:

- Wash solution A: 50 % formamide (p.A., catalog No. 9684, Merck, Darmstadt), 2x SSC.
- Wash solution B: 0.1x SSC.
- Wash solution C: 4x SSC, 0.1 % Tween 20.
- Wash solution D: 2x SSC, 0.05 % Tween 20.
- Blocking solution: 3 % BSA, 4x SSC, 0.1 % Tween 20.
- Detection buffer: 1 % BSA, 4x SSC, 0.1 % Tween 20.
- Anti-digoxigenin rhodamine, FAB fragments (catalog No. 1207750, Boehringer Mannheim)
- Antifade solution: 0.233 g DABCO (1,4-diazabicyclo-2,2,2-octane), 20 mM Tris-HCl, pH 8.0, 90 % glycerol.
- 4,6-diamino-2-phenylindole (DAPI)

Detailed course:

1. Wash solutions A and B were heated in a water bath in a cuvette to 42°C.
2. The seal ring of liquid adhesive was removed from the cover glass which was then washed in wash solution A at 42°C for 3 x 10 min.
3. Thereafter, washing was carried out in wash solution B for 3 x 10 min.
4. 200 µl of the blocking solution were pipetted onto the cover glass, a cover glass was again placed thereon and incubated at 37°C in a moist chamber for 30 min.
5. The blocking solution was removed; 200 µl of the detection buffer having 6 µg/ml rhodamine-conjugated anti-digoxigenin (Boehringer, Mannheim) were placed on

TEST PAGE 760

the cover glass instead and incubated under a cover glass at 37°C in a moist chamber for 30 min.

6. The large cover glass with the cell nuclei was then washed in wash solution C at 42°C three times for 10 min. each.
7. Thereafter, the large cover glass with the cell nuclei was incubated in 2x SSC in which 200 ng/ml (DAPI) were dissolved for 20 min.
8. Washing of the cover glass in wash solution D at room temperature for 1 to 2 min.
9. Covering the hybridized interphase nuclei with antifade solution.

Step 4

Isolation of the hybridized nuclei by micromanipulation

Apparatus:

Microscope Axioskop FS (Carl Zeiss, Jena, Germany) equipped for fluorescence microscopy.

De Fonbrune micromanipulator (Bachofer, Reutlingen, Germany).

De Fonbrune "microforge" (Mikroschmiede) (Bachofer, Reutlingen) for the production of microtips.

Glass plates from B270: size 70 x 35 mm, thickness 6 mm; with step: width 26 mm, depth 4 mm. (Produced by Berliner Glas KG, Waldkraichburger Straße 5, 12347 Berlin, Germany, order No. B 100158 - PO / e h).

Detailed course:

1. The large cover glass with the Colo cell nuclei to be isolated was placed on the B270 glass plate (with the cells facing downwards); the intermediate space between base bottom and cover glass (and cell nuclei, respectively) was filled with antifade solution.
2. A microtip produced in the microforge was inserted in the micromanipulator. The microtip was extended by means of the microforge such that it faced upwards at an angle of about 30°.
3. The microtip was then pushed into the intermediate space filled with the antifade solution, so that its lower portion reached the cell nuclei to be isolated.
4. The Colo nuclei could be made visible under fluorescent conditions by a suitable filter (filter set No. 487915-9901 for rhodamine or filter set No. 487901-9901 for DAPI, Carl Zeiss, Jena) under the microscope. By using transmitted light it was also possible to simultaneously recognize the microtip. In this way, it was possible to "pick up" the cell nuclei individually onto the microtips. (Remark: Since the cell nuclei are not brittle in the antifade solution but resilient, they can be isolated as a whole).
5. Having picked up one nucleus each with a needle, the latter was broken off at the bottom of a PCR tube filled with 20 µl H₂O. In this way, populations having an accurately defined cell number of hybridized and non-hybridized nuclei could be isolated. (Remark: The non-hybridized cell nuclei had been treated in the same way as the hybridized nuclei but in the *in situ* hybridization no tag-labeled DNA had been added).

Following this step, the isolated nuclei were subjected to DOP PCR. This protocol is identical with step 1 (points 1-5), however, no further starting DNA is added with the exception of the isolated nuclei. The DOP PCR product was used for common CGH analysis (cf. Kallioniemi A., et al., *Science* 258:818, 1992, Kallioniemi O.-P., et al., *Genes Chromosome Cancer*, 10:231, 1994 and Lichter P., et al. in *Human Chromosomes*, eds. Verma R.S. and Babu A., New York, 1995, p. 191). It showed that by means of the process according to the invention between 89 % and 94 % of all chromosome over-representations were recognized in 30 Colo 320(HSR) cells and 10 Colo320 (HSR) cells, respectively, whereas it was only between 38 % and 44 % without the TGH process. In addition, the number of false-positive findings in the TGH-treated group is markedly lower than that of the non-TGH-treated group (7 over 18) (cf. fig. 2).

Claims

1. A process for detecting numerical changes in cell DNA, comprising the following steps:

- (a) isolation of the DNA from normal cells and amplification of the DNA by means of a PCR method using tag primers,
- (b) *in situ* hybridization of cells under study with the amplified DNA from (a),
- (c) amplification of DNA from the *in situ* hybridized cells from (b) by means of a PCR method using the tag primers from (a), and
- (d) identification of numerical changes in the amplified DNA from (c) in a normal way.

2. The process according to claim 1, characterized in that the cells under study originate from tumors.

3. The process according to claim 1, characterized in that the cells under study originate from the blood of pregnant persons.

4. The process according to claim 2 or 3, characterized in that the cells under study are those of a small cell population or single cells.

5. The process according to any one of claims 1 to 4, characterized in that the cells under study have an interphase nucleus.

6. The process according to any one of claims 1 to 5, characterized in that the tag primers are degenerative primers.

7. The process according to any one of claims 1 to 6, characterized in that the identification from (d) comprises a CGH method.
8. A kit for carrying out the process according to any one of claims 1 to 7, comprising the following components:
 - (a) amplified DNA from normal cells, the DNA being flanked by tag primers,
 - (b) tag primers, and common
 - (c) auxiliary agents, particularly those suitable for identifying numerical changes in a DNA.

0001234567890

Abstract of the Disclosure**Identification of Numerical Changes in Cell DNA**

The present invention relates to a process for identifying numerical changes in cell DNA, comprising the following steps:

- (a) isolation of DNA from normal cells and amplification of the DNA by means of a PCR method using tag primers,
- (b) *in situ* hybridization of cells under study with the amplified DNA from (a),
- (c) amplification of DNA from the *in situ* hybridized cells from (b) by means of a PCR method using the tag primers from (a), and
- (c) identification of numerical changes in the amplified DNA from (c) in a normal way.

In addition, the invention concerns a kit suitable for carrying out the process.

PCT/GB97/007475

Amended Claims

1. A process for detecting numerical changes in cell DNA, comprising the following steps:

- (a) isolation of the DNA from cells which have no known numerical changes in their DNA, and amplification of the DNA by means of a PCR method using tag primers,
- (b) *in situ* hybridization of cells under study with the amplified DNA from (a),
- (c) amplification of DNA from the *in situ* hybridized cells from (b) by means of a PCR method using the tag primers from (a), and
- (d) identification of numerical changes in the amplified DNA from (c).

2. The process according to claim 1, characterized in that the cells under study originate from tumors.

3. The process according to claim 1, characterized in that the cells under study originate from the blood of pregnant persons.

4. The process according to claim 2 or 3, characterized in that the cells under study are those of a small cell population or single cells.

5. The process according to any one of claims 1 to 4, characterized in that the cells under study have an interphase nucleus.

6. The process according to any one of claims 1 to 5, characterized in that the tag primers are degenerative primers.

7. The process according to any one of claims 1 to 6, characterized in that the identification from (d) comprises a "Comparative Genomic Hybridization" (CGH) method.
8. A kit for carrying out the process according to any one of claims 1 to 7, comprising the following components:
 - (a) amplified DNA from cells which have no known numerical changes in their DNA, the DNA being flanked by tag primers,
 - (b) tag primers, and
 - (c) auxiliary agents for identifying numerical changes in a DNA.

SEARCHED
INDEXED
SERIALIZED
FILED

EXPRESS MAIL NO. EL185309230US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Stefan JOOS, et al.

Application No. To be Assigned
(Based Upon International
Application No. PCT/DE97/00814)

Filed: Herewith
(International Filing Date: April 23, 1997)

For: **IDENTIFICATION OF NUMERICAL
CHANGES IN CELL DNA**

Art Unit: To Be Assigned

Examiner: To Be Assigned

Attorney's Docket No: 3528.38.US00

SUBSTITUTE SPECIFICATION PURSUANT TO 37 C.F.R. §1.125

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.125, Applicants submit herewith a substitute specification in addition to the English translation of the application filed pursuant to 35 U.S.C. §371.

Applicants submit that it is clear that the amendments made to the specification would make it difficult to examine unless a substitute specification were provided. However, no new matter is added by way of the substitute specification. The changes are purely grammatical and adapt more standard United States patent language. The invention described herein is identical to that described in the priority documents.

In addition, the claim language has been changed to comply with United States claim format. All multiple dependent claims have been changed to depend only from a single claim. The language "wherein" has been substituted for "characterized in that" in accordance with United States practice. Moreover, the passive verbs have been changed to active verbs.

Respectfully submitted,

Date: October 22, 1998

HOWREY & SIMON

1299 Pennsylvania Avenue, N.W., Box 34
Washington, D.C. 20004
(650) 463-8100

J. David Smith Reg. No. 39,839
Albert P. Halluin (Reg. No. 25,227)

IDENTIFICATION OF NUMERICAL CHANGES IN CELL DNA

FIELD OF THE INVENTION

The present invention relates to a process for identifying numerical changes in cell DNA and a kit suitable for carrying out the process.

BACKGROUND OF THE INVENTION

For the field of molecular tumor genetics, it is important to know which genetic changes and cytogenetic changes, are present in certain tumors, in which sequences they form and whether they are correlated with the clinical course. In order to find this out, it is necessary to investigate the DNA of small cell populations of the tumors and single-cells thereof. Many attempts have been made to achieve this goal. However, the previous results are not satisfactory.

SUMMARY OF THE INVENTION

Therefore, it is the object of the present invention to provide a process by which it is possible to identify genetic changes and cytogenetic changes in the DNA of small cell populations and single cells. According to the invention, this is achieved by the subject matters defined in the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides a diagram of the process according to the invention.

Figure 2 provides chromosomal over-representations in the cell line Colo 320HSR with and without use of the "Tagged Genome Hybridization" (TGH) process according to the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a process for detecting numerical changes in cell DNA, which comprises the following steps:

25 (a) isolating DNA from normal cells and amplifying the DNA by PCR using tag primers;
(b) hybridizing of the cells under study *in situ* with amplified DNA from (a);

- (c) amplifying DNA from the *in situ* hybridized cells from (b) by PCR using the tag primers from (a); and
- (d) identifying numerical changes in the amplified DNA from (c) in a normal way.

5 The expression "normal cells" comprises cells of any kind and origin, which have no known numerical changes in their DNA.

DNA is isolated and amplified from such cells. Common methods can be used for this purpose. For the amplification, a PCR method which uses tag primers is appropriate. The expression "tag" refers to the fact that the primers can be degenerative (universal) 10 primers, *i.e.*, primers which can bind to many different sites of a cell DNA. Examples of such primers are DOP or SiA primers.

The expression "cells under study" comprises cells of any kind and origin. In particular, these are tumor cells or cells from the blood of pregnant persons. Cells of a small cell population or single cells are particularly preferred. Most preferred are cells 15 having a nucleus in interphase.

The cells under study are subjected to an *in situ* hybridization with the amplified DNA from healthy cells. For this purpose, common conditions and materials known to those skilled in the art can be used.

The DNA from the *in situ* hybridized cells is used as a template for amplification. 20 For this purpose, a PCR method which uses the above-noted tag primers is preferred.

The amplified DNA is used to determine numerical changes. For this purpose, common methods known to those skilled in the art can be used. It is preferable to carry out a comparative genomic hybridization method (CGH) (Kallioniemi A., et al., *Science* 258:818 (1992); Kallioniemi O.P., et al., *Genes Chromosome Cancer* 10:231 (1994); and 25 Lichter P., et al., *in Human Chromosomes*, eds. Verma R.S. and Babu A., New York, p. 191 (1995)).

According to the invention, a kit is also provided for carrying out the process for identifying numerical changes in the DNA of cells, particularly of a small cell population or single cells. Such a kit comprises the following components:

- 30 (a) amplified DNA from healthy cells, the DNA being flanked by tag primers;
- (b) tag primers, and common; and

(c) auxiliary agents, particularly those suitable for identifying numerical changes in DNA.

By means of the present invention, it is possible to identify numerical changes in the DNA of cells, particularly of small cell populations and single cells. Thus, the 5 present invention is adapted for use in diagnosing of diseases in which the investigation of small tissue samples and cell aggregates matter. Such diseases include tumors. Furthermore, the present invention is suitable for examining embryonic cells in the blood of pregnant persons. Hence, it represents a new method for prenatal diagnostics.

The following example explains the invention.

10

EXAMPLE

Analysis of small cell populations of cell line Colo 320(HSR) by the process according to the invention

The process, according to the invention (the TGH process of Fig. 1), is carried out below with cell line Colo 320 (HSR). The TGH process proceeds in several individual 15 steps as follows:

- Prepare Colo 320(HSR) interphase nuclei on slides.
- Prepare a tag-labeled sequence pool of normal genomic DNA by means of DOP PCR.
- Modify the tag-labeled genomic DNA.
- Hybridize the tag-labeled genomic DNA on interphase nuclei of cell line Colo 320(HSR) *in situ*.
- Isolate Colo 320(HSR) cell populations of defined number by micromanipulation. To elucidate the efficiency of the TGH treatment, both cell nuclei hybridized with tag-labeled DNA and non-hybridized cell 25 nuclei were isolated and then compared.
- Amplify the DNA of the isolated cell nuclei by means of DOP PCR.
- Perform comparative genomic hybridization (CGH) to identify chromosomal imbalances of Colo 320(HSR) cells.

As far as preparing the interphase nuclei, isolating genomic DNA from blood and 30 the CGH protocol are concerned, reference is made to known methods (Kallioniemi A.,

DOCUMENT NUMBER: TPS0

et al., *Science* 258:818 (1992); Kallioniemi O.P., et al., *Genes Chromosome Cancer* 10:231 (1994); and Lichter P., et al. in *Human Chromosomes*, eds. Verma R.S. and Babu A., New York, p 191 (1995)). The teachings of these references are herein incorporated by reference.

5 Step I

Preparation of a tag-labeled sequence pool of normal genomic DNA by means of DOP PCR.

Reagents, buffers and solutions:

- 10x reaction buffer: 20 mM MgCl₂; 500 mM KC1; 100 mM Tris-HCl (pH 8.4); 1 mg/ml gelatin
- 10x nucleotide-mix: 2 mM of each nucleotide dATP, dCTP, dGTP, dTTP (prepared from the deoxynucleoside triphosphate set from Boehringer Mannheim, Germany, Catalog No. 1277049).
- 15 L0x DOP primer: 20 μ M of oligonucleotide 5'CCG ACT CGA GNN NNN NAT GTG G3', (N = A, C, G or T).
- For minigels: agarose; TBE buffer: 0.089 M Tris-borate, 0.089 M boric acid, 2 mM EDTA (pH 8.0); suitable size marker (e.g., 1 kb marker; catalog No. 15615-016; Gibco BRL, Eggenstein, Germany); gel loading buffer having 0.25% bromophenol blue and 30% glycerol.
- 20 Starting DNA of normal cells, to be labeled and amplified.

Detailed course:

1. The following components were pipetted on ice into a 500 μ l reaction vessel (PCR vessels having integrated volume restriction; Sarstedt, Nümbrecht, Germany) (total volume 50 μ l):

- 25 100 ng genomic starting DNA;
- 5 μ l 10x reaction buffer;
- 5 μ l 10x nucleotide mix;
- 5 μ l 10x DOP primer;

H₂O add to 50 μ l; and

1.25 U taq polymerase (should be added last).

2. The same components were transferred with a pipette as negative control but without the addition of the starting DNA.

5 3. A device from Omniprobe/Hybaid (Type AZ 1623; supplier MWG Biotech Ebersbach near München, Germany) was used for the PCR reactions. The following temperature program was employed:

- initial denaturation of the starting DNA by heating to 93°C for 10 min.
- 5 cycles (what is called "low stringency phase") each with:
10 94°C, 1 min. ; 30°C, 3 min.; 30°C-72°C, 3 min.; 72°C, 3 min.
- 35 cycles (what is called "high stringency phase") each with:
94°C, 1 min.; 62°C, 1 min.; 72°C, 3 min. (with an extension of 1 sec/cycle).
- a final extension step at 72°C for 10 min.

15 4. After the PCR reaction, an aliquot of 7 μ l of the product was separated on an agarose gel. A 1 kb marker served as the size marker. The separation was made in 1x TBE buffer with 100 V for 30 min. The applied DNA was made visible by staining using ethidium bromide and photographed. A "smear" with DNA fragments between 200 base pairs and 2000 base pairs was usually visible. No DNA was identifiable within this size 20 range in the negative control.

5. Finally, the rest of the nucleotides were separated from the tag-labeled DNA by means of a PCR purification kit (Diagen GmbH, Hilden, Germany, catalog No. 28106).

Step 2

25 Modification of the tag-labeled genomic DNA for the *in situ* hybridization.

Reagents, buffers and solutions:

- 10x reaction buffer with 0.5 M Tris-HCl (pH 8.0), 50 mM MgCl₂, 0.5 mg/ml bovine serum albumin (fraction V, catalog No. 735078, Boehringer Mannheim).

26274774 P60

- 0.1 M β -mercaptoethanol.
- 10x nucleotide stock solution with 0.5 mM dATP, 0.5 mM dCTP, 0.5 mM dGTP, 0.125 mM digoxigenin-11-dUTP (Boehringer Mannheim, catalog No. 1558706), 0.375 mM dTTP.
- 5 - Escherichia coli-DNA-polymerase I (New England Biolabs GmbH, Schwalbach/Taunus, Germany, catalog No. 209L).
- DNase I stock solution: 3 mg in 1 ml 0.15 M NaCl, 50% glycerol.
- Column buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.1% SDS.
- Columns: Sephadex GSO (medium), 1 ml tuberculin syringes (e.g.,
- 10 - Primoll from Pharmoplast A/S, DK-4970 Rodby), glass wool.
- For Minigel: Agarose; TBE buffer; 1 kb size marker (Gibco BRL, Eggenstein, catalog No. 15615-016); gel loading buffer (see above).

Detailed course:

1. 2 μ g of the tag-labeled DNA (see step 1) were transferred with a pipette into a reaction vessel together with 10 μ g of the 10x reaction buffer, 10 μ l β -mercaptoethanol, 10 μ l of the nucleotide stock solution, 20 U of DNA-polymerase I, and 2 μ l of a 1:1000 dilution of the DNase stock solution (in water).
- 15 2. The modification reaction was carried out at 15°C for 30-40 min.
3. The reaction mixture was placed on ice and an aliquot was tested for the
- 20 fragment size suitable for the *in situ* hybridization.
4. The fragment length of the DNA was determined by gel electrophoresis. 10 μ l of the reaction batch were admixed with 3 μ l gel loading buffer and denatured in the boiling water bath for 2-3 min. After another 3 min. on ice, the aliquot was applied to a 1-2% agarose minigel, together with the 1 kb size marker. The DNA fragments were
- 25 separated with 15 V/cm for 30 min. After staining using ethidium bromide, the gel could be photographed under U.V. light and the size of the DNA fragments could be determined.
5. In the optimum case, the DNA fragments should have a size range between 500 and 1000 base pairs. When the average size of the fragments was above this

range, the remaining DNA was incubated once again with DNase I until the optimum size of the fragments was reached.

6. In order to inactivate the DNase, 2 μ l of 0.5 M EDTA (final concentration 10 mM) and 1 μ g 10% SDS (final concentration 0.1%) were added to the batch and the 5 reaction batch was heated at 68°C for 10 min.

7. Non-incorporated nucleotides were separated from the DNA sample by gel filtration using separation columns, which had been produced as follows.

10 (a) A 1 ml tuberculin syringe was initially packed with glass wool up to the 0.2 ml mark and then filled with buffered Sephadex G50 up to the 1 ml mark. The column was transferred into a 15 ml vessel and centrifuged at 2000 g and room temperature for 6 min.

15 (b) After adding 100 μ l of column buffer each, the columns were centrifuged again. This step was repeated three times.

(c) The DNA was placed on the column, centrifuged (2000 g, 6 min.) and collected in a reaction vessel. The final concentration of this DNA sample is about 20 ng/ μ l. It can be stored at -20°C over a prolonged period of time (months to years).

Step 3

20 *In situ* hybridization of the tag-labeled genomic DNA on interphase nuclei of line Colo 320(HSR).

A. Denaturation of the genomic DNA of the Colo 320 (HSR) interphase nuclei.

Reagents, buffers and solutions:

25 - Denaturation solution: 70% deionized formamide (for molecular biology, catalog No. 112027, Merck, Darmstadt, 2x SSC, 50 mM sodium phosphate (pH 7 with 1 M HCl).
- ethanol (ice-cold): 70%, 90% and 100%.

Detailed course:

1. The denaturation solution was placed in a cuvette and heated in a water bath to 70°C.

2. The cover glasses (76 x 26 mm) including the Colo 320(HSR) cell nuclei under study were incubated in this solution for 2 min. precisely and then immediately 5 transferred into the cold 70% alcohol.

3. The cover glasses were dehydrated in 70%, 90% and 100% ethanol for 5 min. each and then air-dried.

B. Precipitation and denaturation of the tag-labeled DNA sample for the *in situ* hybridization.

10 *Reagents, buffers and solutions*

- 3 M sodium acetate, pH 5.2.
- Deionized formamide (for molecular biology, catalog No. 112027, Merck, Darmstadt). The deionization was made by stirring the formamide with an ion exchanger (e.g., AG 501-X8 (D) Resin, catalog No. 142-6425 of 15 Biorad, München, Germany).
- 2x hybridization buffer: 4x SSC, 20% dextran sulfate.

Detailed course:

1. 1 µg of the tag-labeled DNA and 50 µg of human Cot1 DNA (Gibco-BRL, Eggenstein, catalog No. 5279SA) were precipitated by adding 1/20 volume of 3 M 20 sodium acetate and 2.5 volumes of 100% ethanol.

2. After centrifuging at 12,000 rpm and 4°C for 10 min., the supernatant was separated, the pellet was washed with 500 µl 70% ethanol, centrifuged again (12,000 rpm, 10 min., 4°C) and then lyophilized.

25 3. The precipitated DNA was inserted in 6 µl deionized formamide and shaken at room temperature for 30 min. (Vortex).

4. After adding 6 µl of 2x hybridization buffer, shaking was carried out again for 30 min.

5. The DNA was denatured at 75°C for 5 min., placed on ice for 5 min. and then incubated at 37°C for 30 min. ("preannealing").

C. En situ hybridization.

Detailed course:

5 1. 12 µ of the hybridization mix including the denatured DNA were placed on a large cover glass comprising the cell nuclei under study.

2. A cover glass having a size of 18 x 18 mm was placed thereon.

3. The 18 x 18 mm cover glass was sealed with liquid adhesive, and the preparation was incubated in a moist chamber at 37°C for 48 h.

10 D. Washing and detection of the hybridized cell nuclei.

Reagents, buffers and solutions:

- Wash solution A: 50% formamide (p.A. catalog No. 9684, Merck, Darmstadt), 2x SSC.

- Wash solution B: 0.1x SSC.

15 - Wash solution C: 4x SSC, 0.1% Tween 20.

- Wash solution D: 2x SSC, 0.05% Tween 20.

- Blocking solution: 3% BSA, 4x SSC, 0.1% Tween 20.

- Detection buffer: 1% BSA, 4x SSC, 0.1% Tween 20.

- Anti-digoxigenin rhodamine, FAB fragments (catalog No. 1207750, 20 Boehringer Mannheim)

- Antifade solution: 0.233 g DABCO (1,4-diazabicyclo-2,2,2-octane), 20 mM Tris-HCl, pH 8.0, 90 % glycerol.

- 4,6-diamino-2-phenylindole (DAPI)

Detailed course:

25 1. Wash solutions A and B were heated in a water bath in a cuvette to 42°C.

2. The seal ring of liquid adhesive was removed from the cover glass which was then washed in wash solution A at 42°C for 3 x 10 min.
3. Thereafter, washing was carried out in wash solution B for 3 x 10 min.
4. 200 µl of the blocking solution were pipetted onto the cover glass, a cover glass was again placed thereon and incubated at 37°C in a moist chamber for 30 min.
5. The blocking solution was removed; 200 µl of the detection buffer having 6 µg/ml rhodamine-conjugated anti-digoxigenin (Boehringer, Mannheim) were placed on the cover glass instead and incubated under a cover glass at 37°C in a moist chamber for 30 min.
- 10 6. The large cover glass with the cell nuclei was then washed in wash solution C at 42°C three times for 10 min. each.
7. Thereafter, the large cover glass with the cell nuclei was incubated in 2x SSC in which 200 ng/ml (DAPI) were dissolved for 20 min.
8. Washing of the cover glass in wash solution D at room temperature for 15 1 to 2 min.
9. Covering the hybridized interphase nuclei with antifade solution.

Step 4

Isolation of the hybridized nuclei by micromanipulation.

Apparatus:

- 20 Microscope Axioskop FS (Carl Zeiss, Jena, Germany) equipped for fluorescence microscopy.
- De Fonbrune micromanipulator (Bachofer, Reutlingen, Germany).
- De Fonbrune "microforge" (Mikroschmiede) (Bachofer, Reutlingen) for the production of microtips.
- 25 Glass plates from B270: size 70 x 35 mm, thickness 6 mm; with step: width 26 mm, depth 4 mm. (Produced by Berliner Glas KG, Waldkraichburger Straße 5, 12347 Berlin, Germany, order No. B 100158 - PO / e h).

Detailed course:

1. The large cover glass with the Colo cell nuclei to be isolated was placed on the B270 glass plate (with the cells facing downwards); the intermediate space between base bottom and cover glass (and cell nuclei, respectively) was filled with antifade solution.

5 2. A microtip produced in the microforge was inserted in the micromanipulator. The microtip was extended by means of the microforge such that it faced upwards at an angle of about 30%.

3. The microtip was then pushed into the intermediate space filled with the antifade solution, so that its lower portion reached the cell nuclei to be isolated.

10 4. The Colo nuclei could be made visible under fluorescent conditions by a suitable filter (filter set No. 487915-9901 for rhodamine or filter set No. 487901-9901 for DAPI, Carl Zeiss, Jena) under the microscope. By using transmitted light, it was also possible to simultaneously recognize the microtip. In this way, it was possible to "pick up" the cell nuclei individually onto the microtips. (Remark: Since the cell nuclei are not 15 brittle in the antifade solution but resilient, they can be isolated as a whole).

5. Having picked up one nucleus each with a needle, the latter was broken off at the bottom of a PCR tube filled with 20 μ l H₂O. In this way, populations having an accurately defined cell number of hybridized and non-hybridized nuclei could be isolated. (Remark: The non-hybridized cell nuclei had been treated in the same way as the 20 hybridized nuclei, but in the *in situ* hybridization no tag-labeled DNA had been added).

Following this step, the isolated nuclei were subjected to DOP PCR. This protocol is identical with step 1 (points 15), however, no further starting DNA is added with the exception of the isolated nuclei. The DOP PCR product was used for common CGH analysis (Kallioniemi A., et al., *Science* 258:818 (1992); Kallioniemi O.P., et al., 25 *Cancer Chromosome Cancer* 10:231 (1994); and Lichter P., et al. *in Human Chromosomes*, eds. Verma R.S. and Babu A., New York, p. 191 (1995)). It showed that by means of the process according to the invention between 89% and 94% of all chromosome over-representations were recognized in 30 Colo 320(HSR) cells and 10 Colo320 (HSR) cells, respectively, whereas it was only between 38% and 44% without 30 the TGH process. In addition, the number of false-positive findings in the TGH-treated group is markedly lower than that of the non-TGH-treated group (7 over 18) (Fig. 2).

CLAIMS

1. A process for detecting numerical changes in cell DNA, comprising the following steps:

- (a) isolating DNA from cells which have no known numerical changes in their DNA, and amplifying the DNA by means of a PCR method using tag primers;
- (b) hybridizing of cells under study *in situ* with the amplified DNA from (a);
- (c) amplifying DNA from the *in situ* hybridized cells from (b) by means of a PCR method using the tag primers from (a); and
- (d) identifying numerical changes in the amplified DNA from (c).

5

2. The process according to claim 1, wherein the cells under study originate from tumors.

10

3. The process according to claim 1, wherein the cells under study originate from the blood of pregnant persons.

15

4. The process according to claim 1, wherein the cells under study are those of a small cell population or single cells.

20

5. The process according to claim 1, wherein the cells under study have a nucleus in interphase.

6. The process according to claim 1, wherein the tag primers are degenerative primers.

25

7. The process according to claim 1, wherein the identifying is performed by a "Comparative Genomic Hybridization" (CGH) method.

8. A kit for carrying out the process according to claim 1, comprising the following components:

- (a) amplified DNA from cells that have no known numerical changes in their DNA, the DNA being flanked by tag primers;

- (b) tag primers; and
- (c) auxiliary agents for identifying numerical changes in a DNA.

ABSTRACT OF THE DISCLOSURE

The present invention relates to a process for identifying numerical changes in cell DNA, comprising the following steps:


- (a) isolating DNA from normal cells and amplifying the DNA by means of a
5 PCR method using tag primers;
- (b) hybridizing cells under study *in situ* with the amplified DNA from (a);
- (c) amplifying DNA from the *in situ* hybridized cells from (b) by means of a
10 PCR method using the tag primers from (a), and
- (d) identifying numerical changes in the amplified DNA from (c) in a normal
way.

In addition, the invention concerns a kit suitable for carrying out the process.


SEARCHED
INDEXED
MAILED

1/2
Diagram of "Tagged Genome Hybridization"

1.) Preparation of a representative tag-labeled DNA pool from genomic DNA of normal cells by means of a universal PCR method.



2.) *In situ* hybridization of interphase nuclei with tag-labeled DNA pool.



3.) Universal PCR of the isolated interphase nuclei with identical primers (see step a)




Fig. 1

Detection sensitivity of chromosomal over-representations in Colo 320(HRS) cells following universal PCR (DOP PCR) and CGH

Genomic DNA
30 nuclei
10 nuclei
5 nuclei
1 nucleus




Fig. 2

Combined Declaration and Power of Attorney for Patent Application

As a below named inventor, I hereby declare that

Docket Number: 03528.0038.US00

My residence, post office address and citizenship are as stated below next to my name

I believe I am an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled IDENTIFICATION OF NUMERICAL CHANGES IN CELL DNA, the specification of which is attached hereto unless the following box is checked:

■ was filed on October 22, 1998;
as United States Application Number or PCT International Application Number 09/171,854; and
was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION(S)

Application No.	Country	(Day/Month/Year/Filed)	Priority Claimed
19616381.1	Germany	24 April 1996	<input checked="" type="checkbox"/> Yes No
PCT/DE97/00814	PCT	23 April 1997	<input checked="" type="checkbox"/> Yes No
			<input type="checkbox"/> Yes No
			<input type="checkbox"/> Yes No

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

<u>Application No.</u>	<u>Filing Date</u>

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

Application No.	Filing Date	(Status - patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Ray L. Auerbach, Reg. No. 32,680
 Kelvin L. Barnes, Jr. Reg. No. 38,375
 Thane Bazu, Reg. No. P41,604
 Michael J. Bell, Reg. No. 39,604
 John A. Bendrick, Reg. No. P41,612
 Mark R. Buscher, Reg. No. 35,006
 Celine T. Callahan, Reg. No. 34,301
 Cono A. Carrano, Reg. No. 39,623
 Joseph V. Colaianni, Reg. No. 39,948
 James F. Davis, Reg. No. 21,072
 Thomas M. Duham, Reg. No. 39,965
 Joel M. Freed, Reg. No. 25,101

Vernon Randall Gard, Reg. No. 33,886
 Alan M. Grimaldi, Reg. No. 26,599
 Alexander J. Hadjis, Reg. No. 36,540
 Albert P. Halluin, Reg. No. 25,227
 Michael N. Haynes, Reg. No. 40,014
 Rouget F. Henschel, Reg. No. 39,221
 Leslie L. Jacobs, Jr., Reg. No. 40,659
 Richard H. Kjeldgaard, Reg. No. 30,186
 Joseph P. Lavelle, Reg. No. 31,036
 David R. Marsh, Reg. No. 41,408
 Kevin W. McCabe, Reg. No. 41,182
 Joseph A. Micallef, Reg. No. 39,772

Anthony D. Miller, Reg. No. 34,394
 Karen L. Nicastro, Reg. No. 35,968
 Bradley J. Olson, Reg. No. 40,750
 Russell O. Paige, Reg. No. P40,758
 Andrew Y. Piatnicz, Reg. No. 40,772
 Andrew G. Reister, Reg. No. 36,253
 Stephen J. Rosenman, Reg. No. 39,209
 Timothy L. Scott, Reg. No. 37,931
 Anthony W. Shaw, Reg. No. 30,104
 J. David Smith, Reg. No. 39,839
 Michael J. Songer, Reg. No. 39,841

Send Correspondence to:

Albert P. Halluin
HOWREY & SIMON
 Box No. 34
 1299 Pennsylvania Avenue, N.W.
 Washington, D.C. 20004-2402
 Facsimile: (202) 383-7195

Direct Telephone Calls to: (202) 783-0800

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR: <u>Stefan JOOS</u>	CITIZENSHIP: <u>Germany</u>
RESIDENCE: <u>Platanenweg 3, 69221 Dossenheim GERMANY</u>	DATE: <u>Nov. 13, 1998</u>
POST OFFICE ADDRESS: <u>Platanenweg 3, 69221 Dossenheim GERMANY</u>	INVENTOR'S SIGNATURE: <u>Stefan Joos</u>
FULL NAME OF SECOND INVENTOR: <u>Peter LICHTER</u>	CITIZENSHIP: <u>Germany</u>
RESIDENCE: <u>Am Großen Wald 36, 69251 Gaiberg GERMANY</u>	DATE: <u>Nov. 13, 1998</u>
POST OFFICE ADDRESS: <u>Am Großen Wald 36, 69251 Gaiberg GERMANY</u>	INVENTOR'S SIGNATURE: <u>Peter Lichter</u>
FULL NAME OF THIRD INVENTOR:	CITIZENSHIP:
RESIDENCE:	DATE:
POST OFFICE ADDRESS:	INVENTOR'S SIGNATURE:
(Supply similar information and signature for subsequent joint inventors, if any)	